NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 129 filers reported holding NOVOCURE LTD in Q4 2017. The put-call ratio across all filers is 0.22 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $2,132,000 | -18.2% | 25,314 | -27.4% | 0.02% | -21.1% |
| Q3 2019 | $2,606,000 | +46.5% | 34,856 | +24.0% | 0.02% | +35.7% |
| Q2 2019 | $1,779,000 | +1772.6% | 28,121 | +1329.6% | 0.01% | +1300.0% |
| Q1 2019 | $95,000 | +41.8% | 1,967 | -0.7% | 0.00% | 0.0% |
| Q4 2018 | $67,000 | -92.5% | 1,981 | -88.4% | 0.00% | -88.9% |
| Q3 2018 | $892,000 | +2187.2% | 17,013 | +1274.2% | 0.01% | +800.0% |
| Q2 2018 | $39,000 | +387.5% | 1,238 | +218.3% | 0.00% | – |
| Q4 2017 | $8,000 | 0.0% | 389 | 0.0% | 0.00% | – |
| Q3 2017 | $8,000 | -83.3% | 389 | -85.9% | 0.00% | -100.0% |
| Q2 2017 | $48,000 | +1500.0% | 2,764 | +610.5% | 0.00% | – |
| Q1 2017 | $3,000 | 0.0% | 389 | 0.0% | 0.00% | – |
| Q4 2016 | $3,000 | 0.0% | 389 | 0.0% | 0.00% | – |
| Q3 2016 | $3,000 | -25.0% | 389 | 0.0% | 0.00% | – |
| Q2 2016 | $4,000 | – | 389 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $39,681,000 | 20.12% |
| HARTLINE INVESTMENT CORP/ | 330,672 | $27,866,000 | 5.97% |
| MORGAN JESS S & CO INC | 52,889 | $4,457,000 | 4.37% |
| Darsana Capital Partners LP | 1,350,000 | $113,765,000 | 3.88% |
| Rhenman & Partners Asset Management AB | 350,000 | $29,495,000 | 3.23% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $843,000 | 2.55% |
| Taylor Frigon Capital Management LLC | 38,073 | $3,208,000 | 2.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,500 | $2,991,000 | 1.08% |
| Granite Investment Partners, LLC | 261,315 | $22,021,000 | 1.04% |
| Nicholas Investment Partners, LP | 85,835 | $7,233,000 | 0.74% |